Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Department of Geriatrics, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Mediators Inflamm. 2023 Aug 16;2023:5513245. doi: 10.1155/2023/5513245. eCollection 2023.
BACKGROUND: Ferroptosis, a newly discovered mode of cell death, emerges as a new target for atherosclerosis (AS). Long noncoding RNAs (lncRNAs) are involved in the regulation of ferroptosis. In our previous study, lnc-MRGPRF-6:1 was highly expressed in patients with coronary atherosclerotic disease (CAD) and closely associated with macrophage-mediated inflammation in AS. In the present study, we aim to investigate the role of lnc-MRGPRF-6:1 in oxidized-low-density lipoprotein (ox-LDL)-induced macrophage ferroptosis in AS. METHODS: Firstly, ox-LDL-treated macrophages were used to simulate macrophage injury in AS. Then, ferroptosis-related biomarkers and mitochondrial morphology were detected and observed in ox-LDL-treated macrophages. Subsequently, we constructed lnc-MRGPRF-6:1 knockdown and overexpression of THP-1-derived macrophages and investigated the role of lnc-MRGPRF-6:1 in ox-LDL-induced ferroptosis. Then human monocytes were isolated successfully and were used to explore the role of lnc-MRGPRF-6:1 in macrophage ferroptosis. Likely, we constructed lnc-MRGPRF-6:1 knockdown and overexpression of human monocyte-derived macrophages and detected the expression levels of ferroptosis-related biomarkers. Then, transcriptome sequencing, literature searching, and following quantitative real-time polymerase chain reaction and western blot were implemented to explore specific signaling pathway in the process. It was demonstrated that lnc-MRGPRF-6:1 may regulate ox-LDL-induced macrophage ferroptosis through glutathione peroxidase 4 (GPX4). Eventually, the correlation between lnc-MRGPRF-6:1 and GPX4 was measured in monocyte-derived macrophages of CAD patients and controls. RESULTS: The ox-LDL-induced injury in macrophages was involved in ferroptosis. The knockdown of lnc-MRGPRF-6:1 could alleviate ox-LDL-induced ferroptosis in macrophages. Meanwhile, the overexpression of lnc-MRGPRF-6:1 could intensify ox-LDL-induced ferroptosis. Furthermore, the knockdown of lnc-MRGPRF-6:1 could alleviate the decrease of GPX4 induced by RAS-selective lethal compounds 3 (RSL-3). These indicated that lnc-MRGPRF-6:1 may suppress GPX4 to induce macrophage ferroptosis. Eventually, lnc-MRGPRF-6:1 was highly expressed in the monocyte-derived macrophages of CAD patients and was negatively correlated with the expression of GPX4. CONCLUSION: lnc-MRGPRF-6:1 can promote ox-LDL-induced macrophage ferroptosis through inhibiting GPX4.
背景:铁死亡是一种新发现的细胞死亡方式,它成为动脉粥样硬化(AS)的新靶点。长链非编码 RNA(lncRNA)参与铁死亡的调控。在我们之前的研究中,lnc-MRGPRF-6:1 在冠心病(CAD)患者中高表达,并与 AS 中巨噬细胞介导的炎症密切相关。本研究旨在探讨 lnc-MRGPRF-6:1 在氧化低密度脂蛋白(ox-LDL)诱导的 AS 巨噬细胞铁死亡中的作用。
方法:首先,用 ox-LDL 处理巨噬细胞模拟 AS 中巨噬细胞损伤。然后,检测 ox-LDL 处理的巨噬细胞中的铁死亡相关生物标志物和线粒体形态。随后,构建 THP-1 衍生巨噬细胞的 lnc-MRGPRF-6:1 敲低和过表达,并探讨 lnc-MRGPRF-6:1 在 ox-LDL 诱导的铁死亡中的作用。然后成功分离人单核细胞,并用于探讨 lnc-MRGPRF-6:1 在巨噬细胞铁死亡中的作用。同样,构建 lnc-MRGPRF-6:1 敲低和过表达的人单核细胞衍生巨噬细胞,并检测铁死亡相关生物标志物的表达水平。然后进行转录组测序、文献检索以及定量实时聚合酶链反应和 Western blot 检测,以探讨该过程中的特定信号通路。结果表明,lnc-MRGPRF-6:1 可能通过谷胱甘肽过氧化物酶 4(GPX4)调节 ox-LDL 诱导的巨噬细胞铁死亡。最终,在 CAD 患者和对照组的单核细胞衍生巨噬细胞中测量 lnc-MRGPRF-6:1 与 GPX4 的相关性。
结果:ox-LDL 诱导的巨噬细胞损伤涉及铁死亡。lnc-MRGPRF-6:1 的敲低可减轻 ox-LDL 诱导的巨噬细胞铁死亡。同时,lnc-MRGPRF-6:1 的过表达可加重 ox-LDL 诱导的铁死亡。此外,lnc-MRGPRF-6:1 的敲低可减轻 RAS 选择性致死化合物 3(RSL-3)引起的 GPX4 减少。这表明 lnc-MRGPRF-6:1 可能通过抑制 GPX4 诱导巨噬细胞铁死亡。最终,lnc-MRGPRF-6:1 在 CAD 患者的单核细胞衍生巨噬细胞中高表达,并与 GPX4 的表达呈负相关。
结论:lnc-MRGPRF-6:1 可通过抑制 GPX4 促进 ox-LDL 诱导的巨噬细胞铁死亡。
Mediators Inflamm. 2023
Altern Ther Health Med. 2023-4
Biology (Basel). 2022-9-23
Clin Hemorheol Microcirc. 2024
Front Cell Dev Biol. 2025-8-11
BMC Biol. 2025-6-6
Front Cardiovasc Med. 2025-4-16
J Inflamm Res. 2025-3-17
Front Cell Dev Biol. 2024-12-9
Chin Med J (Engl). 2024-9-6
Noncoding RNA Res. 2024-5-20
Cell Death Discov. 2022-10-30
Oxid Med Cell Longev. 2022-8-5
Antioxidants (Basel). 2022-6-27
Nat Rev Cardiol. 2023-1
Oxid Med Cell Longev. 2022-4-18
J Clin Invest. 2022-5-16